Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company, engages in the development of DNA-based vaccines and immunotherapies. The company offers a pipeline of product candidates that address a range of infections and cancer. Its product candidates in Phase III clinical development include VGX-3100, a vaccine for the treatment of cervical dysplasia and genital warts; and […]